Mitral valvular regurgitation. Etiology, pathophysiologic mechanisms, clinical manifestations

Herz, Supplement

Volumn 31, Issue 1, 2006, Pages 6-13

  Boudoulas, Harisios ^a,b,c,d,e   Sparks, Elizabeth E ^a   Wooley, Charles F ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b BIOMEDICAL RESEARCH FOUNDATION   (Greece)

^c Department of Medicine/Cardiology and Pharmacy ^*

^d Hellenic Cardiological Society

^e Center for Clinical Research   (Sweden)

Author keywords

Floppy mitral valve; Mitral regurgitation, chronic, acute; Pathophysiology

Indexed keywords

ERGOTAMINE; FENFLURAZONE PLUS PHENTERMINE; METHYSERGIDE; PHENTERMINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AGING; ARTICLE; BACTERIAL ENDOCARDITIS; CLINICAL FEATURE; DIAGNOSTIC IMAGING; HEMODYNAMICS; HUMAN; IMAGE ANALYSIS; INDUSTRIALIZATION; ISCHEMIC HEART DISEASE; LABORATORY TEST; LIFE EXPECTANCY; MIGRAINE; MITRAL VALVE PROSTHESIS; MITRAL VALVE REGURGITATION; MITRAL VALVE REPAIR; MUCOCUTANEOUS LYMPH NODE SYNDROME; PATHOPHYSIOLOGY; RHEUMATIC FEVER; RHEUMATIC HEART DISEASE; SYMPTOM; TRANSLUMINAL VALVULOPLASTY; BIOLOGICAL MODEL; MITRAL VALVE; REVIEW; BIOTECHNOLOGY; CARDIAC PATIENT; CLINICAL PRACTICE; CORRELATION ANALYSIS; DISEASE COURSE; HEALTH CARE; IMAGING; INCIDENCE; LABORATORY; MEDICAL TECHNOLOGY; MORPHOLOGY;

HUMANS; MITRAL VALVE; MITRAL VALVE INSUFFICIENCY; MODELS, CARDIOVASCULAR;

EID: 33646577773     PISSN: 09461299     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00059-006-2777-y     Document Type: Article

References (23)

1. Boudoulas H, Wooley CF. Mitral valve: floppy mitral valve, mitral valve prolapse, mitral valvular regurgitation, 2nd edn. Armonk: Futura, 2000.
2. Carabello BA, Crawford FA. Valvular heart disease. N Engl J Med 1997;337:32-41.
3. Boudoulas H. Valvular disease. American College of Cardiology self-assessment program (ACCSAP 6), Book 4. Bethesda: American College of Cardiology, 2005:14.1-149.
4. Borer JS, Bonow RO. Contemporary approach to aortic and mitral regurgitation. Circulation 2003;108:2432-8.
5. Boudoulas H. Etiology of valvular heart disease in the 21st century. Hell J Cardiol 2002;43:183-8.
6. Disse S, Abergel E, Berrebe A, et al. Mapping of a first locus for autosomal dominant myxomatous mitral-valve prolapse to chromosome 16p11.2-p12-1. Am J Hum Genet 1999;65:1242-51.
7. LeMarec H, Trochu JN, Schott JJ, et al. Mapping of a gene for an X-linked myxomatous valvular disease. In: Boudoulas H, Wooley CF, eds. Mitral valve: floppy mitral valve, mitral valve prolapse, mitral valvular regurgitation. Armonk: Futura, 2000:191-209.
8. Roberts R. Another chromosomal locus for mitral valve prolapse: close but no cigar. Circulation 2005;112:1924-6.
9. Salustri A, Becker AE, van Herwerden L, et al. Three-dimensional echocardiography of normal and pathologic mitral valve: a comparison with two-dimensional transesophageal echocardiography. J Am Coll Cardiol 1996;27:1502-10.
10. Pennell D. Cardiovascular magnetic resonance. Heart 2001;85:581-9.
11. Boudoulas H, Wooley CF. Floppy mitral valve/mitral valve prolapse/mitral valvular regurgitation: effects on the circulation. J Cardiol 2001;37:Suppl I:15-20.
12. Marorn K, Yacoub MH, Polak JM, et al. Innervation of human atrioventricular and arterial valves. Circulation 1996;94:368-75.
13. Boudoulas H, Toutouzas P, Wooley CF. Functional abnormalities of the Aorta. Armonk: Futura, 1996.
14. Boudoulas H. Involvement of other structures of the heart and other disease processes induced by renal failure. In: Leier CV, Boudoulas H, eds. Cardiorenal disorders and diseases. Mount Kisco: Futura, 1992:192-225.
15. Robbins JD, Mancar PB, Cotts W, et al. Prevalence and severity of mitral regurgitation in chronic systolic heart failure. Am J Cardiol 2003;91:360-2.
16. Lamas GA, Mitchell GF, Flaker GC, et al. Clinical significance of mitral regurgitation after acute myocardial infarction. Survival and ventricular enlargement. Circulation 1997;96:827-33.
17. Komeda M, Glasson JR, Bolger AE, et al. Geometric determinants of ischemic mitral regurgitation. Circulation 1997;96:11-33.
18. Marcus RH, Sareli P, Pocock WA, et al. The spectrum of severe rheumatic mitral disease in a developing country. Correlations among clinical presentation, surgical pathologic findings and hemodynamic sequelae. Ann Intern Med 1004;120:177-83.
19. Soler-Soler J. Valve disease. Worldwide perspective of valve disease. Heart 2000;83:516-26.
20. Asherson RA, Cervera R. Antiphospholipid antibodies and the heart. Lessons and pitfalls for the cardiologist. Circulation 1991;84:920-3.
21. Fox CS, Vasan RS, Parise H, et al. Mitral annular calcification predicts cardiovascular morbidity and mortality. Circulation 2003;107:1492-6.
22. Weissman NJ, Tighe JF, Gottdiener JS, et al., Sustained-Release Dexfenfluramine Study Group. An assessment of heart-valve abnormalities in obese patients taking dexfenfluramine, sustained-release dexfenfluramine or placebo. N Engl J Med 1998;339:725-32.
23. Boudoulas KD, Sparks EA, Rittgers SE, et al. Factors determining left atrial kinetic energy in patients with chronic mitral valve disease. Herz 2003;28:437-44.